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Global Survey of Clinical Oncology 
Workforce
INTRODUCTION
Globally, cancer is the second leading cause of 
death.1 Although we know that cancer mortality 
rates are dropping in United States, even within 
the country, glaring cancer health disparities 
exist.2 In countries with less advanced health 
care facilities, cancer incidence and mortality 
continues to rise.1 In most of these regions, the 
mortality-to-incidence ratio is distressingly high, 
resulting in a profound burden on public health 
and the economy. Cancer accounts for > 200 
million disability-adjusted life years worldwide.3
A lack of access to resources to diagnose and 
treat cancer is a major hindrance to the equi-
table delivery of cancer care. In several regions 
of the world, access to cancer prevention and 
early diagnosis are suboptimal. The poor quality 
of cancer registries in low and middle-income 
countries results in a glaring knowledge defi-
cit that adversely impacts cancer health care 
delivery. Access to affordable cancer treatment 
using chemotherapy, targeted therapy, or radio-
therapy is another major impediment to global 
cancer control. In addition to these tremendous 
challenges, inadequate availability of health care 
professionals contributes to cancer health dispar-
ities. A shortage of > 2,300 medical oncologists 
in the United States is anticipated in 2025.4 It 
is an undeniable fact that there is a profound 
shortage of oncologists in several parts of the 
world; however, the magnitude of this problem is 
poorly described in the literature. The aim of this 
study was to survey and describe the availability 
of clinical oncologists around the world.
METHODS
Articles that provided data on the number of clini-
cal oncologists that were published after January 
1, 2007, and that provided data over any time 
period during the last 10 years were identified by 
using searches on PubMed and Google Scholar. 
In addition, searches were performed on profes-
sional society Web sites, documents, and gov-
ernment records that were obtained from the 
ministry of health Web sites of various countries. 
Data obtained from professional societies, gov-
ernment or health authority sources, research 
surveys, and expert opinions were considered to 
be valid for the purpose of this study. If there 
are multiple sources of data for a specific coun-
try, the most recent data were used if the source 
was deemed to be more reliable than the previ-
ous one. Because a nonsystematic search was 
conducted, a flow diagram will not be reported. 
A lack of well-trained clinical oncologists can result in significant cancer health disparities. The 
magnitude of this problem around the world is poorly described in the literature. A comprehensive 
global survey of the clinical oncology workforce was conducted. Data on the number of clinical 
oncologists in 93 countries were obtained from 30 references. The mortality-to-incidence ratio 
was estimated by using data on incidence and mortality rates from the GLOBOCAN 2012 database; 
the ratio was > 70% in 26 countries (28%), which included 21 countries in Africa (66%) and 
five countries in Asia (26%). Eight countries had no clinical oncologist available to provide care 
for patients with cancer. In 22 countries (24%), a clinical oncologist would provide care for 
< 150 patients with a new diagnosis of cancer. In 39 countries (42%), a clinical oncologist would 
provide care for > 500 patients with cancer. In 27 countries (29%), a clinical oncologist would 
provide care for > 1,000 incident cancers, of which 25 were in Africa, two were in Asia, and 
none were in Europe or the Americas. The economic and social development status of a country 
correlates closely with the burden of cancer and the shortage of human resources. Addressing the 
shortage of clinical oncologists in regions with a critical need will help these countries meet the 
sustainable development goals for noncommunicable diseases by 2030.
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Given the nature of the research question, such 
a search strategy is not expected to impact the 
validity of the study findings.
To obtain estimates on cancer incidence and 
mortality rates at the country level, the GLOBOCAN 
model—produced by International Agency for 
Research on Cancer—was used.5 It provides 
estimates on cancer incidence and mortality for 
2012. The ratio of newly diagnosed patients with 
cancer per clinical oncologist was ascertained for 
each country. For the purpose of this study, the 
mortality-to-incidence ratio was computed from 
the incidence and mortality estimates for 2012 
provided by the GLOBOCAN model. The eco-
nomic status of countries was classified into low-, 
lower middle-, upper middle-, and high-income 
groups on the basis of gross national income by 
per capita calculated by using the World Bank 
Atlas method.6 The social development of a 
country was defined by the Sociodemographic 
Index (SDI), which was derived from measures 
of education, income, and fertility, and classified 
into low, low-middle, middle, high-middle, and 
high SDI categories.3
RESULTS
Data on the number of clinical oncologists were 
obtained for 93 countries from 30 unique refer-
ences7-36 (Tables 1 and 2). It included 32 coun-
tries in Africa, 21 from Asia and Australia, 31 
from Europe, and nine from North and South 
America.
Economic Status and SDI
The economic status of 20 countries was cate-
gorized as low income, and 19 were categorized 
as low SDI. Two countries were categorized as 
low economic income but had low-middle SDI 
(Zimbabwe and Nepal). Two countries that were 
categorized as low SDI were deemed lower 
middle–income countries using the World Bank 
definition (Cote d’Ivoire and Mauritania).
Mortality-to-Incidence Ratio
The mortality-to-incidence ratio was > 70% in 
26 countries (28%) and < 50% in 23 (25%). 
In Africa, the mortality-to-incidence ratio was 
> 70% in 21 countries (66%) and < 50% in none. 
In Asia, the mortality-to-incidence ratio was 
> 70% in five countries (26%) and < 50% in 
three (16%). The mortality-to-incidence ratio 
was > 70% in none of the countries in Europe 
or the Americas. The mortality-to-incidence ratio 
was > 50% in 13 countries (42%) in Europe and 
seven countries (100%) in South America.
Ratio of New Diagnosed Patients With Cancer 
Per Clinical Oncologist
There were eight countries with no clinical oncol-
ogist available to provide care for patients with 
cancer (Fig 1). In 22 countries (24%), a clinical 
oncologist would provide care for < 150 patients 
with a new diagnosis of cancer. In 39 countries 
(42%), a clinical oncologist would provide care 
for > 500 patients with cancer, of which 26 
countries were in Africa (81%), nine were in Asia 
(47%), two were in Europe (6%), and two were 
in South America (29%). An extreme shortage of 
clinical oncologists—> 1,000 incident cancers 
per clinical oncologist—existed in 25 countries 
in Africa (78%) and two countries (11%) in Asia. 
None of the countries in Europe or North or 
South America faced such an extreme shortage 
of clinical oncologists.
DISCUSSION
This study identifies significant disparity in the 
availability of clinical oncologists among the 93 
countries surveyed. To my knowledge, this is the 
most comprehensive survey of the clinical oncol-
ogy workforce in the world. In addition to high-
lighting the critical burden of cancer in Africa, 
the study identifies an extreme shortage of clini-
cal oncologists on the continent as well. The sit-
uation was only slightly better in Asia. Compared 
with the burden of cancer in Africa and Asia, the 
situation in Europe and the Americas seems to 
be better; however, there are major disparities 
among the countries on these continents too. 
The majority of countries in South America had a 
mortality-to-incidence ratio of > 50%. Similarly, 
42% of countries in Europe had a mortality-to- 
incidence ratio of > 50%; however, compared 
with Africa and Asia, the availability of the clinical 
oncology workforce seems to be better in Europe 
and North and South America.
This global survey study has several limitations. 
Although the study is comprehensive and pro-
vides data for 93 countries, there are no data 
on the number of clinical oncologists for sev-
eral countries; however, previous studies on the 
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Table 1. Availability of the Clinical Oncology Workforce
Region/Country
Sociodemographic 
Index
Economic 
Status
Annual Cancer 
Incidence, No.
Annual Cancer 
Mortality, No.
Mortality-to-
Incidence 
Ratio
No. of 
Clinical 
Oncologists
Ratio of New Cancer 
Cases Per Clinical 
Oncologist
Africa
Angola Low-middle UMI 10,000 7,200 0.72 24 417
Benin Low LI 5,000 3,800 0.76 4 1,250
Botswana Middle UMI 1,600 1,000 0.63 6 267
Burkina Faso Low LI 7,800 6,200 0.79 3 2,600
Burundi Low LI 7,000 5,700 0.81 0 No oncologist
Central African 
Republic
Low LI 2,800 2,200 0.79 0 No oncologist
Chad Low LI 6,000 4,700 0.78 0 No oncologist
Cote d’Ivoire Low LMI 12,000 9,300 0.78 4 3,000
Democratic 
Republic of 
Congo
Low LI 37,000 31,000 0.84 4 9,250
Egypt Middle LMI 115,000 72,000 0.63 1,500 77
Ethiopia Low LI 61,000 45,000 0.74 6 10,167
Gabon Middle UMI 1,000 620 0.62 4 250
Ghana Low-middle LMI 16,000 11,000 0.69 10 1,600
Kenya Low-middle LMI 41,000 28,000 0.68 6 6,833
Malawi Low LI 15,000 11,000 0.73 1 15,000
Mali Low LI 9,000 7,000 0.78 2 4,500
Mauritania Low LMI 1,800 1,300 0.72 1 1,800
Mauritius High-middle UMI 2,600 1,500 0.58 11 236
Morocco Low-middle LMI 35,000 23,000 0.66 28 1,250
Mozambique Low LI 22,000 17,000 0.77 4 5,500
Namibia Middle UMI 1,300 800 0.62 4 325
Nigeria Low-middle LMI 102,000 72,000 0.71 26 3,923
Rwanda Low LI 8,300 6,200 0.75 0 No oncologist
Senegal Low LI 6,800 4,900 0.72 12 567
Sierra Leone Low LI 2,800 2,200 0.79 0 No oncologist
South Africa Middle UMI 77,000 47,000 0.61 40 1,925
South Sudan Low LI 8,700 6,600 0.76 0 No oncologist
Tanzania Low-middle LI 34,000 24,000 0.71 6 5,667
Togo Low LI 3,700 2,800 0.76 0 No oncologist
Uganda Low LI 29,000 22,000 0.76 6 4,833
Zambia Low-middle LMI 11,000 7,500 0.68 5 2,200
Zimbabwe Low-middle LI 16,000 11,000 0.69 4 4,000
Asia
Afghanistan Low LI 20,000 15,000 0.75 0 No oncologist
Bangladesh Low-middle LMI 123,000 91,000 0.74 150 820
Bhutan Low-middle LMI 500 380 0.76 2 250
China Middle UMI 3,065,000 2,206,000 0.72 25,600 120
Georgia High-middle UMI 12,000 7,300 0.61 350 34
India Middle LMI 1,015,000 683,000 0.67 1,500 677
(Continued on following page)
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Table 1. Availability of the Clinical Oncology Workforce
Region/Country
Sociodemographic 
Index
Economic 
Status
Annual Cancer 
Incidence, No.
Annual Cancer 
Mortality, No.
Mortality-to-
Incidence 
Ratio
No. of 
Clinical 
Oncologists
Ratio of New Cancer 
Cases Per Clinical 
Oncologist
Indonesia Middle LMI 300,000 195,000 0.65 932 322
Iran High-middle UMI 85,000 53,000 0.62 325 262
Iraq Middle UMI 26,000 17,000 0.65 60 433
Israel High HI 29,000 11,000 0.38 250 116
Japan High HI 704,000 379,000 0.54 867 812
Kazakhstan High-middle UMI 40,000 24,000 0.6 126 317
Lebanon High-middle UMI 9,000 4,800 0.53 100 90
Malaysia High-middle UMI 37,000 22,000 0.59 64 578
Nepal Low-middle LI 19,000 14,000 0.74 45 422
Oman High-middle HI 1,500 900 0.6 30 50
Pakistan Low-middle LMI 148,000 101,000 0.68 175 846
Philippines Middle LMI 98,000 59,000 0.60 242 612
Sri Lanka High-middle LMI 24,000 14,000 0.58 18 1,333
Australia
Australia High HI 122,000 43,000 0.35 448 272
New Zealand High HI 21,000 9,000 0.43 40 525
Europe
Austria High HI 41,000 20,000 0.49 426 96
Belgium High HI 65,000 30,000 0.46 212 307
Bulgaria High-middle UMI 32,000 18,000 0.56 90 356
Czech 
Republic
High HI 58,000 27,000 0.47 293 198
Denmark High HI 36,000 16,000 0.44 156 231
Estonia High HI 6,000 3,600 0.6 52 115
Finland High HI 28,000 11,000 0.39 208 135
France High HI 349,000 155,000 0.44 813 429
Germany High HI 494,000 218,000 0.44 2,899 170
Greece High-middle HI 41,000 28,000 0.68 336 122
Hungary High HI 50,000 30,000 0.6 586 85
Iceland High HI 1,500 530 0.35 15 100
Ireland High HI 21,000 8,400 0.4 186 113
Italy High HI 354,000 170,000 0.48 2,724 130
Latvia High HI 10,000 6,000 0.6 72 139
Lithuania High HI 15,000 8,300 0.55 86 174
Malta High-middle HI 2,000 820 0.41 7 286
The 
Netherlands
High HI 93,000 43,000 0.46 348 267
Norway High HI 28,000 11,000 0.39 210 133
Poland High HI 152,000 95,000 0.63 1,468 103
Portugal High-middle HI 49,000 24,000 0.49 256 191
Romania High-middle UMI 79,000 48,000 0.61 270 293
Russia High UMI 458,000 296,000 0.65 1,700 269
Serbia High-middle UMI 42,000 26,000 0.62 54 778
Slovenia High HI 11,000 5,900 0.54 31 355
(Continued on following page)
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oncology workforce shortage have focused 
on specific countries or regions and do not pro-
vide a global overview of the issue as the current 
study does.9,23,25,30,31 Data are collated from dif-
ferent types of sources. Some are from profes-
sional societies or government sources; however, 
some are based on the opinion of experts. Most 
expert opinions are from individuals who collec-
tively provide the estimates within the purview 
of a symposium or a survey, but some are indi-
vidual perspectives that are based on personal 
experience working in a country. Oncology is not 
a recognized subspecialty in several countries, 
and, therefore, accurate estimates are hard to 
obtain; however, the data on the number of clini-
cal oncologists are for individuals who exclusively 
care for patients with cancer. In some countries, 
such as India, it is possible that data on clini-
cal oncologists include radiotherapists, who are 
more qualified in administering radiation than in 
prescribing chemotherapy. The training program 
for clinical oncologists and radiotherapists are 
different in both duration and scope; therefore, 
it is possible that the data for such countries are 
an overestimate. Data on the number of oncol-
ogists are collated over a 10-year period. With 
the exception of three countries, data on number 
of clinical oncologists are collated over a 5-year 
period (2011 to 2015). Regardless, it is unlikely 
that the pattern of the oncology workforce short-
age will be any different if the time period was 
restricted to a single year. Finally, the estimates 
for annual cancer incidence and mortality that 
were obtained from GLOBOCAN 2012 could be 
imprecise as the data are obtained from cancer 
registries with variable quality. Nevertheless, the 
incidence and mortality data from GLOBOCAN 
2012 is recognized universally as the best esti-
mates on cancer burden currently available in a 
public domain.
There are several ways that we can improve the 
situation of the shortage of clinical oncologists. 
International organizations, such as the WHO 
and Union for International Cancer Control, and 
professional societies, such as ASCO and the 
European Society of Medical Oncology, can col-
laborate to conduct a global study on the avail-
ability of human resources for tackling cancer. 
Such a study should ideally involve a precise 
estimation of not just the clinical oncology work-
force, but also of radiotherapists and surgical 
oncologists. An accurate estimation of human 
resources and the strengthening of cancer 
5  jgo.org JGO – Journal of Global Oncology
Table 1. Availability of the Clinical Oncology Workforce
Region/Country
Sociodemographic 
Index
Economic 
Status
Annual Cancer 
Incidence, No.
Annual Cancer 
Mortality, No.
Mortality-to-
Incidence 
Ratio
No. of 
Clinical 
Oncologists
Ratio of New Cancer 
Cases Per Clinical 
Oncologist
Spain High-middle HI 216,000 103,000 0.48 1,216 178
Sweden High HI 50,000 22,000 0.44 415 120
Switzerland High HI 42,000 16,000 0.38 299 140
Turkey High-middle UMI 148,000 92,000 0.62 400 370
Ukraine High-middle LMI 141,000 87,000 0.62 1,935 73
United 
Kingdom
High HI 328,000 158,000 0.49 476 689
North America
Canada High HI 182,000 74,000 0.41 517 352
United States High HI 1,604,000 617,000 0.38 11,700 137
South America
Argentina High-middle UMI 115,000 66,000 0.57 400 287
Brazil High-middle UMI 438,000 225,000 0.51 2,577 170
Chile High-middle HI 40,000 25,000 0.63 60 667
Mexico High-middle UMI 148,000 79,000 0.53 352 420
Panama High-middle UMI 5,400 2,900 0.54 10 540
Peru High-Middle UMI 43,000 26,000 0.60 130 331
Uruguay High-middle HI 13,000 9,000 0.69 120 108
Abbreviations: HI, high income; LI, low income; LMI, lower middle income; UMI, upper middle income.
(Continued)
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Table 2. Details of the Survey 
Region/Country First Author Year of Reporting Type of Data Source
Description of the Type of Clinical 
Oncologist
Africa
Angola Nelson7 2011-2013 Survey of pathologists Oncologists
Benin Nelson7 2011-2013 Survey of pathologists Oncologists
Botswana Nelson7 2011-2013 Survey of pathologists Oncologists
Burkina Faso Nelson7 2011-2013 Survey of pathologists Oncologists
Burundi Nelson7 2011-2013 Survey of pathologists Oncologists
Cameroon Nelson7 2011-2013 Survey of pathologists Oncologists
Central African Republic Nelson7 2011-2013 Survey of pathologists Oncologists
Chad Nelson7 2011-2013 Survey of pathologists Oncologists
Cote d’Ivoire Nelson7 2011-2013 Survey of pathologists Oncologists
Democratic Republic of 
Congo
Nelson7 2011-2013 Survey of pathologists Oncologists
Egypt Stefan8 2013 Expert opinion Clinical oncologists
Ethiopia Nelson7 2011-2013 Survey of pathologists Oncologists
Gabon Nelson7 2011-2013 Survey of pathologists Oncologists
Ghana Parikh9 2014 Expert opiniona Oncologists
Kenya Morgan10 2012 Expert opinion Medical oncologists
Madagascar Nelson7 2011-2013 Survey of pathologists Oncologists
Malawi Nelson7 2011-2013 Survey of pathologists Oncologists
Mali Nelson7 2011-2013 Survey of pathologists Oncologists
Mauritania Nelson7 2011-2013 Survey of pathologists Oncologists
Mauritius Nelson7 2011-2013 Survey of pathologists Oncologists
Morocco Boutayeb11 2013 Health authorities from all cancer 
centers
Medical oncologists
Mozambique Nelson7 2011-2013 Survey of pathologists Oncologists
Namibia Nelson7 2011-2013 Survey of pathologists Oncologists
Niger Nelson7 2011-2013 Survey of pathologists Oncologists
Nigeria Parikh9 2014 Expert opinionb Oncologists
Republic of Congo Nelson7 2011-2013 Survey of pathologists Oncologists
Rwanda Nelson7 2011-2013 Survey of pathologists Oncologists
Senegal Nelson7 2011-2013 Survey of pathologistsc Oncologists
Sierra Leone Nelson7 2011-2013 Survey of pathologists Oncologists
South Africa Nelson7 2011-2013 Survey of pathologists Oncologists
South Sudan Nelson7 2011-2013 Survey of pathologists Oncologists
Tanzania The Foundation 
for Cancer Care in 
Tanzania12
2014 WHO datad Oncologists
Togo Nelson7 2011-2013 Survey of pathologists Oncologists
Uganda Parikh9 2014 Expert opinione Oncologists
Zambia Nelson7 2011-2013 Survey of pathologists Oncologists
Zimbabwe Parikh9 2014 Expert opinion Oncologists
Asia
Afghanistan Are13 2015 Expert opinionf Oncologists
Bangladesh Parikh9 2014 Expert opinion Oncologists
Bhutan Parikh9 2014 Expert opinion Oncologists
(Continued on following page)
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Table 2. Details of the Survey 
Region/Country First Author Year of Reporting Type of Data Source
Description of the Type of Clinical 
Oncologist
China Yang14 2012 Health authorities Oncologists
Georgia Silbermann15 2015 Expert opinion Oncologists
India Parikh9 2014 Expert opinion Oncologists
Indonesia Awofeso16 2011 Expert opinion Oncologists
Iran Bayat17 2015 Survey of government data and 
hospitals
Medical oncologists
Iraq Parikh9 2014 Expert opinion Oncologists
Israel Efrati18 2015 Expert opinion Oncologists
Japan Takiguchi19 2013 Survey of government designated 
cancer hospitals
Medical oncologists
Kazakhstan Silbermann15 2013 Expert opinion Oncologists
Lebanon Piana20 2012 Expert opinion Medical oncologists
Malaysia Daily Express21 2012 Government data Clinical oncologists
Nepal Parikh9 2014 Expert opinion Oncologists
Oman Parikh9 2014 Expert opinion Oncologists
Pakistan Parikh9 2014 Expert opinion Oncologists
Philippines Noh22 2016 Professional societyg Medical oncologists
Sri Lanka Parikh9 2014 Expert opinion Oncologists
United Arab Emirates Parikh9 2014 Expert opinion Oncologists
Australia
Australia Australian Institute 
of Health and 
Welfare23
2015 Government data Medical oncologists
New Zealand Bidwell24 2009 Government data Medical oncologists
Europe
Austria De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Belgium  De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Bulgaria De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Czech Republic Eurostat26 2014 Health authoritiesh
Denmark Eurostat26 2014 Health authoritiesh
Estonia Eurostat26 2014 Health authoritiesh
Finland De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
France De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Germany De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Greece Eurostat26 2014 Health authoritiesh
(Continued on following page)
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Table 2. Details of the Survey 
Region/Country First Author Year of Reporting Type of Data Source
Description of the Type of Clinical 
Oncologist
Hungary De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Iceland Eurostat26 2014 Health authoritiesh
Ireland Eurostat26 2014 Health authoritiesh
Italy De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Latvia Eurostat26 2014 Health authoritiesh
Lithuania Eurostat26 2014 Health authoritiesh
Malta Eurostat26 2014 Health authoritiesh
The Netherlands De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Norway Eurostat26 2014 Health authoritiesh
Poland Eurostat26 2014 Health authoritiesh
Portugal De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Romania Silbermann15 2015 Expert opinion Medical oncologists
Russia Russian Society of 
Clinical Oncology27
2011 Professional societyg Clinical oncology
Serbia Eurostat26 2014 Health authoritiesh
Slovenia Eurostat26 2014 Health authoritiesh
Spain Rivera28 2014 Health authorities Medical oncologists
Sweden De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
Switzerland Eurostat26 2014 Health authoritiesh
Turkey Artac36 2015 Expert opinion Medical oncologists
Ukraine Chekhun29 2013 Expert opinion based on 
governmental statistics
Medical oncologists
United Kingdom De Azambuja25 2015 Survey from professional 
societies, health authorities and 
professionals
Medical oncologists
North America
Canada Canadian Medical 
Association30
2015 Professional society using data 
from the Canadian Medical 
Association Masterfile
Medical oncologists
United States Vose31 2015 Professional society using 
data from American Medical 
Association Masterfile
Hematology/medical oncologists
South America
Argentina Costanzo32 2007 Professional society Medical oncologists
Brazil Strasser-Weippl33 2013 Census Medical oncologists
Chile Jimenez de la 
Jara34
2015 Professional society Medical oncologists
Mexico Strasser-Weippl33 2014 Professional society Clinical oncologists
(Continued on following page)
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registries will be an important step toward reach-
ing the sustainable development goal of reducing 
noncommunicable disease by one third by 2030. 
Training programs must be instituted in regions 
with an extreme shortage of clinical oncologists. 
Governments in countries with a shortage of clin-
ical oncologists will need to urgently design mea-
sures to address challenges within their regions. 
Nontraditional approaches, such as training and 
equipping primary care providers and nurses, 
can be considered in these countries. Countries 
such as Egypt and India that have a well-estab-
lished oncology workforce can be tapped to train 
the health care professionals in their region. 
Instead of utilizing scholarship programs to train 
doctors and nurses from low-income countries 
by sending them to high-income countries, 
the funds could be used to enhance regional 
collaborations. Similarly, oncology workforce devel-
opment can be significantly aided by collabo-
rations between institutions and universities in 
high- and low-income countries.
The economic status of a country and its social 
development status correlate closely with the 
mortality-to-incidence ratio and the availability 
of clinical oncologists. Of these three, improving 
the human resource capacity of a country would 
be a low-hanging fruit for the global oncology 
community. Increasing the availability of clini-
cal oncologists may not improve the quality of 
cancer care. Nevertheless, easier access to a 
trained health care professional will positively 
influence the society. Patients will likely be diag-
nosed at an earlier stage. Various precancerous 
conditions can be diagnosed and managed 
effectively. Curable cancers will be treated with 
9  jgo.org JGO – Journal of Global Oncology
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Fig 1. Graphical  
summary of availability  
of oncologists.
Table 2. Details of the Survey 
Region/Country First Author Year of Reporting Type of Data Source
Description of the Type of Clinical 
Oncologist
Panama Strasser-Weippl33 2015 Expert opinion Clinical oncologists
Peru Goss35 2012 Government data Medical oncologists
Uruguay Strasser-Weippl33 2015 Expert opinion Oncologists
aNelson7 provide the number of clinical oncologists as seven.
bNelson7 provide the number of clinical oncologists as 20.
cData include medical and surgical oncologists.
dNelson7 provide the number of clinical oncologists as ≥ 10.
eNelson7 provides the same estimate.
fData are extrapolated from neighboring countries.
gMembership in society.
hData on the number of oncologists were obtained from a comprehensive European Union survey. Oncologists include clinical oncologists, pediatric oncologists,  
medical oncologists, and hemato-oncologists.
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curative intent. Eventually, more patients with 
cancer will survive the disease.
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